CHICAGO — AbbVie said on Monday that the Food and Drug Administration (FDA) has approved its drug for Parkinson’s disease.
Duopa, which is delivered directly into the small intestine with a portable infusion pump, treats symptoms such as tremors and muscle rigidity. The drug is already approved in Canada and dozens of other countries under the name Duodopa.
About 1 million Americans have Parkinson’s, a disease characterized by reduced levels of dopamine in the brain, which causes slowness, reduced mobility and stiffness, the Parkinson’s Disease Foundation says.
Duopa was approved as an orphan drug, used to treat rare diseases and usually approved with various incentives for the drugmaker.
Most Read Nation & World Stories
- Can you have alcohol after the COVID vaccine?
- After leading a 153-person hike in the Grand Canyon, a Washington health-care exec faces federal charges
- Mom who gave birth on flight didn't know she was pregnant
- Sports on TV & radio: Local listings for Seattle games and events
- Why the world's most vaccinated country is seeing an unprecedented spike in coronavirus cases
“There is unmet need for treatment options for patients with advanced Parkinson’s disease,” said Dr. C. Warren Olanow, lead investigator of the Duopa pivotal trial. “As the disease advances, it can be difficult to control motor features.”
Parkinson’s is characterized by reduced levels of the hormone dopamine in the brain, which leads to poor mobility, slowness and stiffness.